Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis

por Al-Fayoumi, Suliman, Hashiguchi, Taishi, Shirakata, Yuka, Mascarenhas, John, Singer, Jack W
Publicado 2018

Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures

por Singer, Jack W., Al-Fayoumi, Suliman, Taylor, Jason, Velichko, Sharlene, O’Mahony, Alison
Publicado 2019

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor

por Singer, Jack W, Al-Fayoumi, Suliman, Ma, Haiching, Komrokji, Rami S, Mesa, Ruben, Verstovsek, Srdan
Publicado 2016

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies

por Verstovsek, Srdan, Odenike, Olatoyosi, Singer, Jack W., Granston, Tanya, Al-Fayoumi, Suliman, Deeg, H. Joachim
Publicado 2016

Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy

por Singer, Jack W., Fleischman, Angela, Al-Fayoumi, Suliman, Mascarenhas, John O., Yu, Qiang, Agarwal, Anupriya
Publicado 2018